Search | Clinical Trials Finder

Conditions: Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Interventions: RPE (usual care), GXT+THHR (intervention); Behavioral
Lead sponsor: Baystate Medical Center; Other
Eligibility: 60 Years to 99 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Springfield, Massachusetts • Detroit, Michigan

Conditions: Atopic Dermatitis
Interventions: Standard-of-care treatment for AD, Accu-patch pellet; Other · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Substance Use Disorders, Posttraumatic Stress Disorder
Interventions: Modified Seeking Safety integrated into std outpatient SUD care, Standard outpatient SUD care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
Interventions: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor; Procedure · Radiation · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more

Conditions: Thumb Osteoarthritis
Interventions: Video assisted home therapy; Other
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Smoking, Lung Cancer
Interventions: Best Practice, Nicotine Patch, Quality-of-Life Assessment, Questionnaire Administration, Tobacco Cessation Counseling; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 55 Years to 77 Years
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Galveston, Texas • Houston, Texas • Tyler, Texas

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: EG-1962 (nimodipine microparticles), Enteral Nimodipine; Drug
Lead sponsor: Edge Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more

Conditions: Parkinson Disease
Interventions: GM1 ganglioside, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 39 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Blood Pressure, Stroke, Ischemic, Stroke Hemorrhagic
Interventions: Integrated Telehealth After Stroke Care, Usual post-stroke follow-up care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Follow-Up Care, Medical Device Usage and Evaluation, Negative Pressure Wound Therapy, Photography, Questionnaire Administration; Other · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 19 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity
Interventions: Pediatric Obesity Intervention (STANDARD), Pediatric Obesity Intervention + High Activity (ADDED); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: Experimental: Standard vs Intensive e-AT Intervention; Other
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 926 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions: AGuIX, Radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Peer-oriented intervention, Group cognitive behavioral therapy (CBT); Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 74 Years
Enrollment: 746 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congenital Diaphragmatic Hernia, Congenital Abnormalities, Neonatal Diseases and Abnormalities, Hernia, DIaphragmatic, Congenital, Internal Hernia, Hernia, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms
Interventions: Fetal Treatment Arm (FETO Group); Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Elective Cesarean Section, Pain Management
Interventions: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more

Conditions: Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions: Preoperative pelvic floor physical therapy; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis C
Interventions: Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid); Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid-use Disorder
Interventions: OXD01 digital therapy, Standard of Care; Device · Other
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more

Conditions: Glaucoma
Interventions: standard of care, education; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 39
States / cities: Fresno, California • Greenbrae, California • La Jolla, California + 36 more

Conditions: Atrial Fibrillation, Postoperative
Interventions: The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg); Combination Product
Lead sponsor: Helios Cardio Inc.; Industry
Eligibility: 20 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pulmonary Complication, Dyspnea, Pneumonia, COPD, CHF, Atelectasis, PE
Interventions: Incentive Spirometry; Behavioral
Lead sponsor: Jewish Hospital, Cincinnati, Ohio; Other
Eligibility: 65 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Acupressure in Pruritus for Atopic Dermatitis

SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Can Video Assisted Therapy Replace In-Person Occupational Therapy After Hand Surgery: a Noninferiority Study

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

GM1 Ganglioside Effects on Parkinson's Disease

Integrated Telehealth After Stroke Care

A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer

Efficacy of Increasing Physical Activity to Reduce Children's Visceral Fat

Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children

Transformative Research in Diabetic Nephropathy 2.0

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure